	Application Number		10531884
	Filing Date		2006-04-11
INFORMATION DISCLOSURE	First Named Inventor	David	HAIGH
STATEMENT BY APPLICANT	Art Unit	•••••	1626
(Not for submission under 37 CFR 1.99)	Examiner Name	Cheng	g, Karen
	Attorney Docket, Number	r	PG4880USw

***************************************					U.S.F	PATENTS				**********
Examiner Initial <sup>e</sup>	Cite No	Patent Number	Kind Code <sup>1</sup>	issue Da	ais	Name of Patentae or Applicant of cited Document		Pages Columns Lines where Relevant Passages or Releva Figures Appear		
	<b>,</b>	corer:2 cannot read		1898-01-		<u> </u>			,	
if you wis	n to as	dd additional U.S. Pate				ease click the	************************************			
Examiner initial*	Citte No	Publication Number		Publicat			entes or Applicant	Relev	s,Columns,Lines when ant Passages or Reim es Appear	
	1									
If you wis	h to a	dd additionai U.S. Publ	ished Ar					d butto	81.	•••••
	··········	ş	·;······	FOREIC	IN PAT	ENT DOCUS	ients		9% C 5 L	
Examiner Initial*	Cite No	Foreign Document Number®	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patents Applicant of cited Document		Pages, Calumns, Lines where Relevant Passages or Relevan Figures Appear	75
/KC/	1	9029705	wo		A2	1989-08-17	Glycomed Incorpo	rased		
/KC	<u> </u>	99/37204	wo		Ai	1999-07-29	RHONE-POULEN RORER PHARMACEUTIC: INC			
/KC/	(B)	2002/44188	wo		A2	2002-06-06	scios INC.			
£	. 5	i				÷				

07/17/2007 /Karen Cheng/

EFS Web 2.0

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number	10531684
Filing Date	2008-04-11
First Named Inventor	David HAKGH
Art Unit	1626
Examiner Name	Cheng, Karen
Attorney Docket Numbe	r PG4890USW

		•						
/KC/	4	96/33170	wo	A1	1995-10-24	CIBA-GEIGY AG		П
/KC/	5	2004037818	wo	At	2004-05-06	Giaxo Group Limited		
/KC/	8	g3g378g3	wo		2003-05-08			
/KC/	7	G3037895 ·	wo	A1	2003-05-08	Głaxo Group Limited		
if you wist	h to a	<u>l</u> dd additionál Foreign	Patent Documer	it citation	information p	ilease click the Add butto	ń .	<b>.</b>
			NON-PAT	ENT LIT	ERATURE DO	CUMENTS		
Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s).  The publisher, city and/or country where published.						Ţs
/KC/	1	SATO ET AL; Histerodycles; 1994; 37/1; 245-248;						
/KC/	2	P. DE CAPRARIIS, G DE MARTINO, E. ABIGNENTE, P AVARA, L MAYO: Pyrrolo[1,4]benzodiszepines. IV Synthesis of E- and Z-5,11-Dioxo-31a-ethoxycarbonyt-2-ethylidine-1,2,3,10,11,11a-bexahydro-5Hpyrrolo[2,1-o][1,4] benzodiszepine; J. Heterocyclic Chem.; Jan 89, 26, 1023-1027;						
/KC/	3	GARDINER, JAMES ET AL; Synthesis and solid state conformation of phenylalanine mimetics constrained in a proline-like conformation, Organic & Biomolecular Chemistry; 27 July 2004; 2(16): 2365-2370;						
/KC/	4	IKEDA M., ET AL.: Synthesis of trioyotic nitrogen-containing heterocycles by palladium-catalyzed cyclization of 2- alkenyl-n-(o-iodobenzoyt)- and 2-alkenyl-n-(o-iodophenylacetyl)-pyrrolidines; Heterocycles; 1996; 42; pgs. 155-158;						
/KC/		CONFALONE P.N., ET AL.; Design and synthesis of potential DNA cross-linking reagents based on the anthramyoin class of minor groove binding compounds; J. Org. Chem.; 1988; 53; pgs. 482-487;						-

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10531884
Filing Date		2008-04-11
First Named Inventor	David F	HOIAI
Art Unit		1828
Examiner Name	Cheng,	Karen
Attorney Docket Numb	er i	PG4890USw

/KC/	8	ALIG L., ET AL.; Low molecular weight, non-peptide fibrinogen receptor shitagonists; J. Med. Chem.; 1992; 35; pgs. 4393-4407;					
/KC/	(C/ 7 PADWA A., ET AL.; Transmitations of 1,3-dipoles. The conversion of a-diazo hatones into azomethine yildes vis carbonyl yildes; J. Am. Chem. Soc.; 1992; 114; pgs. 593-601;						
/KC/	8.	CULBERTSON T.P., ET AL.; Quincione amibacterial agents substituted at the 7-position with spiricamines. Synthesis and structure-activity relationships; J. Med. Chem.; 1890; 33, pgs. 2270-2275;					
/KC/	/KC/ CROOKS, P.A., ET AL.; Synthesis of 5-hydroxy- and 5.6-dihydroxy-derivatives of spirofindane-2.2'-pyrrolidine], rigid analogues of tyramine and dopamine respectively; Journal of the Chemical Society, Perkins Transactions 1; 1979, 11; [] pgs. 2719-2728;						
/KC/	/KC/ DE MARTINO G., ET AL.; La Reazione Tre 2-Nitrobenzoilaminornalonato 8d Aideide Acrilica Per LA Sintesi Di Composti A Struttura Pirroloj2,1-c) [1,4]Benzodiazepinica (english summary only); Fermaco 8d Sq.; 1976; 31(11); pgs. [[ 786-790]						
/KC/	/KC/ 11 IKEDA ET AL: Journal of the Chemical Society, Parkin Transactions 1: Organic and Bio-Organic Chemistry: 1997: 22; 3339-3344;						
/KC/	/KC/ 12 SATO ET AL; Journal of the Ciremical Society, Perkin Transactions 1; 1995; 14; 1801-1809;						
If you wis	h to a	dd addillonal non-patent literature document citation information please click the Add button					
		EXAMINER SIGNATURE 07/17/2007					
Examine							
*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
See Kind Codes of USPTO Patent Documents at www.USPTO.GGV or MPEP 801.04. Finier office that issued the document, by the two-letter code (VSPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. A Kind of document by the appropriate symbols as indicated on the document under VSPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.							